A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid Malignancies

Clinical trial NCT05263739 · WITHDRAWN

Trial details

NCT number: NCT05263739
Sponsor: Shanghai Escugen Biotechnology Co., Ltd
Status: WITHDRAWN
Phase: Phase 1
Study type: INTERVENTIONAL

B-cell Lymphoid Malignancies

Start date: 2025-12-01
Primary completion: 2026-08-01
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.